{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:33:36Z","timestamp":1787236416641,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"DOI":"10.7759\/cureus.114858","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:29:06Z","timestamp":1787232546000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Primary Sclerosing Cholangitis and Faecal Calprotectin Levels in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Nazar","family":"Abdelgabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltayeb Osman","family":"Elfaki Omer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam Ahmed","family":"Abdel Rahman Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaia Mohammed","family":"TalbAllah Alshiekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Kamal","family":"Ahmed Omer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Elshiekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma Elmansour","family":"Abdalla Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra K","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, et al.. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013, 58:2045-55. 10.1002\/hep.26565","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl16510","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features","volume":"12","author":"Palmela C","year":"2018","unstructured":"Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver. 2018, 12:17-29. 10.5009\/gnl16510","journal-title":"Gut Liver"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis","volume":"21","author":"de Vries AB","year":"2015","unstructured":"de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015, 21:1956-71. 10.3748\/wjg.v21.i6.1956","journal-title":"World J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.07.023","article-title":"Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in\u00a0the\u00a0proximal colon","volume":"16","author":"Krugliak Cleveland N","year":"2018","unstructured":"Krugliak Cleveland N, Rubin DT, Hart J, et al.. Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in\u00a0the\u00a0proximal colon. Clin Gastroenterol Hepatol. 2018, 16:68-74. 10.1016\/j.cgh.2017.07.023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli MH","year":"2015","unstructured":"Mosli MH, Zou G, Garg SK, et al.. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015, 110:802-19; quiz 820. 10.1038\/ajg.2015.120","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.235408","article-title":"Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?","volume":"60","author":"Marelli L","year":"2011","unstructured":"Marelli L, Xirouchakis E, Kalambokis G, Cholongitas E, Hamilton MI, Burroughs AK. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?. Gut. 2011, 60:1224-8. 10.1136\/gut.2010.235408","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2021-102053","article-title":"Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease","volume":"13","author":"Pavlidis P","year":"2022","unstructured":"Pavlidis P, Joshi D, El Sherif Y, et al.. Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease. Frontline Gastroenterol. 2022, 13:497-502. 10.1136\/flgastro-2021-102053","journal-title":"Frontline Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan X","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014, 14:135. 10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout J","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014, 14:25. 10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris CR","year":"2020","unstructured":"Harris CR, Millman KJ, van der Walt SJ, et al.. Array programming with NumPy. Nature. 2020, 585:357-62. 10.1038\/s41586-020-2649-2","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.01.020","article-title":"Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis","volume":"16","author":"Ricciuto A","year":"2018","unstructured":"Ricciuto A, Fish J, Carman N, et al.. Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2018, 16:1098-1105.e1. 10.1016\/j.cgh.2018.01.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.08.041","article-title":"Contrasting pattern of chronic inflammatory bowel disease in primary and autoimmune sclerosing cholangitis","volume":"2","author":"Bjarnason I","year":"2015","unstructured":"Bjarnason I, Hayee B, Pavlidis P, et al.. Contrasting pattern of chronic inflammatory bowel disease in primary and autoimmune sclerosing cholangitis. EBioMedicine. 2015, 2:1523-7. 10.1016\/j.ebiom.2015.08.041","journal-title":"EBioMedicine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2024.106621","article-title":"Unique sterol metabolite shifts in inflammatory bowel disease and primary sclerosing cholangitis","volume":"245","author":"Matysik S","year":"2025","unstructured":"Matysik S, Elger T, Huss M, et al.. Unique sterol metabolite shifts in inflammatory bowel disease and primary sclerosing cholangitis. J Steroid Biochem Mol Biol. 2025, 245:106621. 10.1016\/j.jsbmb.2024.106621","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094765","article-title":"Serum galectin-3 as a non-invasive marker for primary sclerosing cholangitis","volume":"25","author":"Bajraktari G","year":"2024","unstructured":"Bajraktari G, Elger T, Huss M, et al.. Serum galectin-3 as a non-invasive marker for primary sclerosing cholangitis. Int J Mol Sci. 2024, 25:10.3390\/ijms25094765","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-07308-8","article-title":"Elevated long-to-very-long-chain ceramide ratio correlates with disease severity in inflammatory bowel disease and primary sclerosing cholangitis","volume":"15","author":"Elger T","year":"2025","unstructured":"Elger T, Huss M, Liebisch G, et al.. Elevated long-to-very-long-chain ceramide ratio correlates with disease severity in inflammatory bowel disease and primary sclerosing cholangitis. Sci Rep. 2025, 15:20294. 10.1038\/s41598-025-07308-8","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/livers6020015","article-title":"Elevated serum adiponectin levels in primary sclerosing cholangitis (PSC) compared to inflammatory bowel disease (IBD): a potential biomarker for PSC-IBD screening","volume":"6","author":"Elger T","year":"2026","unstructured":"Elger T, Huss M, Loibl J, et al.. Elevated serum adiponectin levels in primary sclerosing cholangitis (PSC) compared to inflammatory bowel disease (IBD): a potential biomarker for PSC-IBD screening. Livers. 2026, 6:15. 10.3390\/livers6020015","journal-title":"Livers"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14071483","article-title":"Elevated serum soluble CD137 in inflammatory bowel disease and primary sclerosing cholangitis highlights a shared immunoregulatory signature","volume":"14","author":"Elger T","year":"2026","unstructured":"Elger T, Huss M, Loibl J, et al.. Elevated serum soluble CD137 in inflammatory bowel disease and primary sclerosing cholangitis highlights a shared immunoregulatory signature. Biomedicines. 2026, 14:10.3390\/biomedicines14071483","journal-title":"Biomedicines"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14071485","article-title":"Reciprocal serum phosphatidylcholine signatures are related to intestinal inflammation in inflammatory bowel disease and liver fibrosis in primary sclerosing cholangitis-an exploratory study","volume":"14","author":"Elger T","year":"2026","unstructured":"Elger T, Huss M, Tews HC, et al.. Reciprocal serum phosphatidylcholine signatures are related to intestinal inflammation in inflammatory bowel disease and liver fibrosis in primary sclerosing cholangitis-an exploratory study. Biomedicines. 2026, 14:10.3390\/biomedicines14071485","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/519301-association-between-primary-sclerosing-cholangitis-and-faecal-calprotectin-levels-in-patients-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:29:07Z","timestamp":1787232547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/519301-association-between-primary-sclerosing-cholangitis-and-faecal-calprotectin-levels-in-patients-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.114858","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}